The absolute estimated levels of colorectal, breast and prostate cancer screening annual utilization in Switzerland in 2014 were 8.1% (colonoscopy), 22.3% (mammography) and 31.3% (PSA testing), respectively. The gene discussed is KLK3; the disease is prostate cancer.